Skip to main content
OpenTrials

Clinical trial condition

Hemic and Lymphatic Diseases

Explore clinical trials studying Hemic and Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

21,085 public trials 3,995 recruiting studies
Refine in advanced search Browse all conditions

Hemic and Lymphatic Diseases trial results

Recruiting

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06449651

Conditions
Blood Platelet Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, +5 more
Locations
  • Universitair Ziekenhuis Leuven Leuven, Belgium
  • Instituto de Medicina Integral Professor Fernando Figueira Recife, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina Da USP São Paulo, Brazil
  • CHRU Lille Lille, France
View all 21 locations
View Trial Details
Recruiting

A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

NCT07572006

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hemic and Lymphatic Diseases, +2 more
Locations
  • Indiana Blood & Marrow Transplantation Indianapolis, Indiana, United States
  • Start Midwest Grand Rapids, Michigan, United States
  • Rutgers Cancer Institute of New Jersey Piscataway, New Jersey, United States
  • NYU Langone Health New York, United States
View all 15 locations
View Trial Details
Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +4 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Cancer Treatment Center of America Phoenix Goodyear, Arizona, United States
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • University of Arkansas at Little Rock Little Rock, Arkansas, United States
View all 262 locations
View Trial Details
Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335

Conditions
Amyloidosis, Blood Protein Disorders, Cardiovascular Diseases, +22 more
Locations
  • City of Hope Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 29 locations
View Trial Details
Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • O Neal Comprehensive Cancer Center at UAB Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • City of Hope Duarte, California, United States
  • City of Hope Orange County Lennar Foundation Cancer Center Irvine, California, United States
View all 71 locations
View Trial Details
Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT05303519

Conditions
Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, IDH-Mutant, Grade 2, +22 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • Mayo Clinic - Arizona Phoenix, Arizona, United States
  • St. Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • University of California San Diego La Jolla, California, United States
View all 61 locations
View Trial Details
Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

NCT06375044

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Mayo Clinic Arizona Phoenix, Arizona, United States
  • Mayo Clinic Florida Jacksonville, Florida, United States
  • Dana Farber Cancer institution Boston, Massachusetts, United States
  • Mayo Clinic Rochester Rochester, Minnesota, United States
View all 16 locations
View Trial Details
Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

NCT07211958

Conditions
Acute Myeloid Leukemias, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Clinical Trial Site Melbourne, Victoria, Australia
  • Clinical Trial Site Nedlands, Western Australia, Australia
  • Clinical Trial Site Perth, Western Australia, Australia
  • Clinical Trial Site Gosford, Australia
View all 109 locations
View Trial Details

Related conditions